<DOC>
	<DOCNO>NCT02393586</DOCNO>
	<brief_summary>The purpose study evaluate bactericidal activity Mycobacterium tuberculosis faropenem boost amoxicillin/clavulanic acid . Pharmacokinetics ( PK ) Whole blood Bactericidal Activity ( WBA ) measure healthy volunteer follow single dos faropenem plus amoxicillin/clavulanic acid .</brief_summary>
	<brief_title>Whole Blood Bactericidal Activity ( WBA ) Against Mycobacterium Tuberculosis Faropenem Plus Amoxicillin/Clavulanic Acid Healthy Volunteers</brief_title>
	<detailed_description>WBA ex vivo model measure combined effect administer drug , host factor strain factor mycobacterial killing . If perform parallel PK measurement , method use evaluate effect drug throughout dose cycle . The aim trial investigate bactericidal activity faropenem administer amoxicillin/clavulanic acid ( augmentin ) use WBA model . We also explore whether additive effect synergy rifampicin model . The activity faropenem WBA different strain M. tuberculosis compare relationship host immune profile WBA assess .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . Aged 21 2 . Male female willing comply study visit procedures 3 . Willing able provide write informed consent 1 . Women currently pregnant breastfeed 2 . Signs active TB 3 . Previous hypersensitivity allergy rifampicin , faropenem betalactam drug ( penicillin , carbapenems ) 4 . Current use drug medication know interaction study drug 5 . Current use drug , counter herbal preparation know potential inhibitor inducer cytochrome P450 enzymes 6 . Evidence renal hepatic dysfunction clinically significant deviation normal screen include laboratory determination 7 . Known hepatic disease alcohol abuse 8 . Any significant condition would , opinion investigator , compromise volunteer 's safety outcome trial 9 . Current participation clinical intervention trial research protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Whole blood Bactericidal Activity</keyword>
	<keyword>WBA</keyword>
	<keyword>Faropenem</keyword>
</DOC>